新闻BenzingaAstraZeneca Has Entered Into An Agreement To Invest $2B In Newly Issued Equity In Summit Therapeutics To Accelerate The Development Of Ivonescimab, A First-In-Class Bispecific Antibody Targeting PD-1 And VEGF, In Combination With Antibody Drug... AstraZeneca Has Entered Into An Agreement To Invest $2B In Newly Issued Equity In Summit Therapeutics To Accelerate The Development Of Ivonescimab, A First-In-Class Bispecific Antibody Targeting PD-1 And VEGF, In Combination With Antibody Drug... Benzinga 2026.09.28 21:37 (GMT+0) 在Benzinga上打开 其他新闻 币安Alpha上线STBL,开放1675枚空投领取 以太坊联创Vitalik批评奈飞FTX题材新剧对CZ的刻画涉嫌种族歧视 今日股票:美光会跌到多低? ANT、NVDA、PANW 等:本周投资者热议不止的 5 只股票 Benzinga的“股票耳语”指数:投资者秘密关注但尚未公开谈论的五只股票 消费科技(11月16日至20日):Anthropic 惊艳亮相,GTA 6 发布等更多内容